drugset / Trial / NCT01845025

Study of Safety of Foradil in Patients With Persistent Asthma

NCT01845025

Phase 4 Terminated 827 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone propionate alone.

Timeline

Start
2013-05
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 100 ug Inhaled
Subject Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Fluticasone propionate Other / unclassified 500 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled

Indications